Funding secured for the first clinical study of BioC wound gel

A rights issue has been completed and successfully raised 14.5 million SEK for Xinnate to fund the first clinical study of BioC wound gel. We plan to begin the study in the fourth quarter of 2021 and will evaluate the safety and antimicrobial and anti-inflammatory effects of BioC in wounds.


Xinnate has received a prestigious Swedish Research Council grant

Xinnate co-founder Artur Schmidtchen has received 9.5 MSEK in funding from the Swedish Research Council – the largest grant awarded in the field of medicine in this round. The application received the highest possible rating in all assessment categories. The money will go to in-depth basic research on mechanisms related to wound healing, which will be commercialized by Xinnate.


Xinnate is looking for a Chief Operating Officer

Chief Operating Officer  - An opportunity to be part of a highly collaborative, international team, turning groundbreaking world class science into clinical applications.

Xinnate is an innovative startup company with the aim to develop and commercialize product concepts for applications in the areas skin, wound, surgery and biomaterials. We specialize in the development of proprietary peptide-based drugs for prevention and treatment of inflammatory diseases and infections. We are in pre-clinical phase, starting clinical trials later this year.

Xinnate is a member of SmiLe incubator at Medicon Village in Lund and we work in close collaboration with the founder prof Artur Schmidtchen and his team at Lund University, BMC.

We are now looking for Chief Operating Officer and the position is a 12 months temporary employment with an option to prolong. Full or part time can be discussed.

Role description

Your main role is to act as on overall project leader directing and coordinating the consultants, CRO’s and the partner involved in the development of the first product. You are responsible for the overall budget and time plan and together with the team you challenge and define the strategic way forward taking into account the regulatory options and the product strategy.

You will also take an active role in developing the documentation needed for the regulatory approval and funding and you will take part in the overall management of the company.

Personal skills and requirements

You have a university degree in life science (MSc) and a PhD or research experience in areas of inflammation and/or infections would be an advantage.

You have a good understanding for pre-clinical project work, and you have previous experience in project coordination. You are skilled in scientific writing and experience from regulatory documentation (IB, IMPD, IND/CTA Application Form, Label design…) would be a benefit.

As a person you are highly motivated, you have a strong drive and you like new challenges. You are structured and take pride in delivering results on time. You are a passionate team player and you are fluent in English with good communication skills.

Application

Pls send you application to Helene.hartman@xinnate.com no later than 2020-02-08.

If you are an applicant and if you have any questions, pls contact Helene Hartman 0725-120312.


Breakthrough results published in Science Translational Medicine

On January 1st the scientific article on the mechanisms and the effect of the wound gel was published in Science Translational Medicine, the highest ranked journal for translational medicine. The article was also chosen to be the cover story for this issue! This both shows the high quality of the work and that the science that Xinnate is based on is truly breakthrough.
Find the article using this link:

A dual-action peptide-containing hydrogel targets wound infection and inflammation - https://stm.sciencemag.org/content/12/524/eaax6601